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Abstract
In rare disease (RD) research, there is a huge need to systematically collect biomaterials, phenotypic, and genomic data in a
standardized way and to make them ﬁndable, accessible, interoperable and reusable (FAIR). RD-Connect is a 6 years global
infrastructure project initiated in November 2012 that links genomic data with patient registries, biobanks, and clinical
bioinformatics tools to create a central research resource for RDs. Here, we present RD-Connect Registry & Biobank Finder,
a tool that helps RD researchers to ﬁnd RD biobanks and registries and provide information on the availability and
accessibility of content in each database. The ﬁnder concentrates information that is currently sparse on different repositories
(inventories, websites, scientiﬁc journals, technical reports, etc.), including aggregated data and metadata from participating
databases. Aggregated data provided by the ﬁnder, if appropriately checked, can be used by researchers who are trying to
estimate the prevalence of a RD, to organize a clinical trial on a RD, or to estimate the volume of patients seen by different
clinical centers. The ﬁnder is also a portal to other RD-Connect tools, providing a link to the RD-Connect Sample Catalogue,
a large inventory of RD biological samples available in participating biobanks for RD research. There are several kinds of
users and potential uses for the RD-Connect Registry & Biobank Finder, including researchers collaborating with academia
and the industry, dealing with the questions of basic, translational, and/or clinical research. As of November 2017, the ﬁnder
is populated with aggregated data for 222 registries and 21 biobanks.
Introduction
Rare diseases (RDs) are usually life-threatening or chroni-
cally debilitating conditions with a very low prevalence and
a high level of complexity. In the EU, a disease is con-
sidered rare when it affects no more than 1 per 2000 persons
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[1], in the United States, when it affects fewer than 200,000
people or about 1 in 1500 people [2]. Though individually
rare, taken together RDs are common. There are around
6000–7000 rare genetic diseases [3], the most rare of which
are estimated to affect about 1/2,000,000 patients [4].
Most RDs are untreatable, and research remains the only
option for patients who are striving to get a right diagnosis
and a treatment for their condition.
For RDs, supporting collaboration and optimizing the
use of limited resources by data sharing is particularly
needed, due to the low individual prevalence and the scar-
city of information related to each disease [5]. We note here
that by data sharing, we do not mean making data public,
but rather controlled access to data under well-deﬁned
conditions [6].
In particular, RD registries, databases, and biobanks
constitute key instruments for increasing knowledge, espe-
cially when they allow the pooling of -omics, clinical, and
phenotypic data [7].
In the past decades, the advent of methods for large-scale
data analyses, and the creation of comprehensive databases
for the hosting and exchange of genetic and clinical data has
allowed researchers to learn and discover more about the
pathogenetic mechanisms underlying the diseases and
response to drugs [8]. In the context of next-generation
sequencing analysis, as well as clinical outcome measures,
the availability of phenotypic data has become key to
increase the chances of providing a molecular diagnosis to
diseases correct gene identiﬁcation [9].
The availability of biomaterials and of clinical and
-omics data has thus become essential to study disease
etiology and pathogenesis paving the way to highly effec-
tive targeted therapies in oncology [10] and in several RDs
(e.g., Ivacaftor and lumacaftor as potentiator and corrector
of CFTR gene for class III CFTR pathogenic variants [11];
Nusinersen for the treatment of spinal muscular atrophy
(SMA), functionally converting splicing of the SMN2 into
SMN1 gene, which codes for survival motor neuron (SMN)
protein [12]).
Funded by the European Union’s Seventh Framework
Programme under the International Rare Diseases Research
Consortium (IRDiRC), a consortium of national and inter-
national funders investing in RD research projects/programs
[13], RD-Connect (http://rd-connect.eu/) is a 6 years global
infrastructure project initiated in November 2012. It aims to
create a uniﬁed system and platform for reprocessing,
sharing, and analyzing -omics data integrated with pheno-
typic data and biological samples [14]. The RD-Connect
Genome-Phenome Analysis Platform (https://platform.rd-
connect.eu/) is designed as key resource for stakeholders of
RD research; including registries, biobanks, researchers,
patients, etc. The platform is created with a view to preserve
patient integrity by involving patient organizations through
active two-way dialog between researchers and patients
[14], as well as support from experts in ethical, legal, and
social issues. RD-Connect is an important partner for Eur-
opean research projects and infrastructures such as the
Biobanking and BioMolecular Resources Research
Infrastructure-European Research Infrastructure Consortium
(BBMRI-ERIC) [15] and ELIXIR, the Distributed Infra-
structure for Life Science Information [16]. Close devel-
opment with partner projects NeurOmics [17] and
EURenOmics [18], implementing -omics technologies in
the study of rare neurological and renal diseases, is ensuring
its usability and relevance of RD-Connect tools for RD
research.
The integration of phenotype data, biosamples, and
-omics data requires coordinated efforts among different
initiatives in order to ensure standardization, comparability,
and reproducibility of research results.
In order to be suitable for integrated data analysis,
sample and phenotype data need to be collected or mapped
into standardized and “computable” form according to
selected ontologies. Ontologies are a way to express con-
cepts in standardized terminology that is ordered in a
hierarchical/tree structure, often with annotations and links
out to other information. Several existing ontologies are
suitable for RD research. RD-Connect, in line with the
IRDiRC, supports the adoption of the Human Phenotype
Ontology (HPO) [19] and the Orphanet Rare Disease
Ontology (ORDO) [20] in RD research.
Currently, the phenotype data that are processed in the
RD-Connect genomics platform are those collected by
partner projects via the software PhenoTips [21], an open
source tool for collecting and analyzing phenotypic infor-
mation for patients with genetic disorders using terms and
annotations from the HPO.
With a view to extending the use of the platform to all
RD researchers, and to promote intense data sharing among
the RD community, including prospective as well as ret-
rospective collections, RD-Connect is providing important
advances for accessing RD patient registries and biobanks at
an international level by developing dedicated catalogues or
resources for RD research [22, 23].
Here, we present the RD-Connect Registry & Biobank
Finder (http://catalogue.rd-connect.eu/), a tool that helps to
ﬁnd RD biobanks and registries and provides information
on the availability and accessibility of content in each
database. RD-Connect Registry & Biobank Finder is also a
portal to other RD-Connect tools, providing a direct link to
the RD-Connect Sample Catalogue, a large inventory of RD
biological samples available in participating biobanks for
RD research (Fig. 1). RD-Connect Sample Catalogue is
designed as a centralized sample-level catalogue, where
researchers can select and request speciﬁc biosamples via
the platform without needing to contact multiple biobanks
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separately for samples of interest. The RD-Connect Sample
Catalogue is currently available as a beta version (https://sa
mples.rd-connect.eu/); the production version is planned for
release in the third quarter of 2017.
RD-Connect Registry & Biobank Finder: a tool for RD
registries and biobanks
In the ﬁeld of RD registries, the possibility to ﬁnd, access,
integrate, and reuse existing data is still limited and there are
many barriers to data sharing. Registries only exist for a
small fraction of RDs and, conversely, more than one reg-
istry exists for certain RDs [24]. Very few registries collect
data in a standardized way; most restrict access to external
users and are not linked to other databases [25]. Information
on the number of RD patients included in a registry is rarely
readily available to external users. Registries may provide
information in periodic reports or in the scientiﬁc literature
or, more rarely, via a public website.
Even though directories of biobanks exist, it is difﬁcult to
understand which biobank to choose from and whether such
biobanks hold trustworthy biological samples for research.
Having identiﬁed potential biobanks, researchers would
then need to navigate individual websites for catalogues to
identify actual biological samples or writing several e-mails
to request information on sample collections.
Currently, several lists and directories of biobanks and
registries are available to the research community on both
common and rare diseases, but none of them is providing
information on the number of patients or samples included
in the databases (Table 1).
The RD-Connect Registry & Biobank Finder is meant
to concentrate information that is currently sparse on dif-
ferent repositories (inventories, databases, websites, sci-
entiﬁc journals, technical reports, etc.), starting from
identifying registries and biobanks that are collecting data
on patients affected by a RD, and on the number of cases
or biological samples included in each database. Such
basic information, if appropriately checked, is fundamental
for any researcher who is trying to estimate the prevalence
of one or more RDs, or for any public or private entity that
is planning to organize a clinical trial on a certain RD and
needs to know if there are enough patients to conduct the
study. This information also provides a view on the
volume of patients seen by the clinical centers that are
coordinating or collaborating with a RD registry, and can
be of interest for the coordination of the newly established
European Reference Networks for care and research on
RD [26, 27].
Establishing a directory of high-quality RD biobanks
linked to a centralized sample catalogue helps researchers to
quickly gain access to relevant biological samples for
experiments [28].
The Finder consists of a standardized view of key ele-
ments of participating databases called ID-Cards (Supple-
mentary Material), in order to provide users with the same
type of information in the same way for all databases, and
increase databases comparability. Key elements include
unique identiﬁers for diseases (ORPHAcodes, OMIM, ICD-
10, etc) that in a linked data environment [29] can be linked
to larger knowledge networks, for instance via mapping
between diseases and phenotypes as provided by the HPO
Project [30].
A human readable ID is displayed in the top left-hand
corner of the ID-Card for each individual biobank and
registry entry. The identiﬁer is mapped to Orphanet iden-
tiﬁers of registries and biobanks.
Technically, the Registry & Biobank Finder is built on an
OpenSource Portal Framework, Liferay [31], and based on
additional OpenSource portlets built in the framework of
RD-Connect. Liferay is one of the leading solutions for
horizontal portals according to Gartner analysis [32]. It is a
Fig. 1 Registry & Biobank
Finder and the RD-Connect
infrastructure. Registry &
Biobank Finder is integrated
with other RD-Connect
elements, in particular the RD-
Connect Sample Catalogue and
the Genomics Platform
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framework based on Java, and enables developers to create
enterprise-grade applications for the web. The system has a
strong built-in security system and a ﬂexible data manage-
ment capability. The platform developed is complementary
to other catalogues like orpha.net [33] and BBMRI catalo-
gue [34] and it is possible to share the information between
these different catalogues.
All users can browse the directory for the registries and/
or biobanks for the RD of interest. Researchers can search
the directory for biobanks or registries jointly or separately
(ﬁlter by type) by biobank/registry name, disease name,
ORPHAcode, OMIM and ICD-10 codes, synonyms, and
other keywords related to the database.
Currently, users can make their search at two different
levels (Fig. 2). The “Catalogue” level (general user reporting
system) displays the list of relevant databases and the total
number of cases registered for all diseases in each database
(Fig. 2a). The “Search” level ﬁlters the results by speciﬁc
RD and displays only the cases of interest. (Fig. 2b). This
ﬁltering function is especially helpful when a researcher
needs to identify speciﬁc RD cases in multi-disease bio-
banks and registries.
More information on a given registry/biobank, is dis-
played in its individual ID-Card, consisting of the “Over-
view”, “Diseases”, and “Documents” sections (Fig. 3). The
Overview provides general information such as address and
contact data, sources of funding, ontologies used, associated
data, and imaging availability, associated biobanks which
are storing biosamples for RD patients included in the
registry with a link to the biobank ID-Cards, and partici-
pation to RD registry networks.
The “Diseases” section contains a “Disease Matrix”
(DM), which is a list indicating the number of RD patients
or biological samples included in a registry or biobank
according to their RD or RD group. Each RD in the DM is
described by the disease name; gene; ORPHAcode; ICD-
10; OMIM number, and synonym(s).
The “Search” strategy of the Registry & Biobank Finder
is based on the information reported in the DM. The level of
detail in the DM may vary according to the level of gran-
ularity used to describe cases or samples through different
coding systems. For example, the cases included in a
database may be described by ORPHAcodes associated to
groups of diseases (e.g., rare genetic neurological disorder),
B
Number of 
cases with 
the disease 
of interest 
in the 
registry or 
biobank.
Search by 
disease 
name, 
OMIM, 
Orpha-
codes, etc.
A
Filter by the 
database 
type: 
registry or 
biobank.
Total 
number of 
cases in the 
registry or 
biobank.
Search by 
disease 
name, 
OMIM, 
Orpha-
codes, etc.
Fig. 2 Search strategies in the
Registry & Biobank Finder. To
help researchers ﬁnd registries
and biobanks, the Registry &
Biobank Finder offers two types
of search engines: “Catalogue”
and “Search”. a In the
“Catalogue” tab, users can search
the directory against different
keywords, such as the disease
name and its synonyms, OMIM-
and Orphacodes (upper left).
The results can be ﬁltered by the
database type and display only
registries or only biobanks
(upper right). The search results
display the list of found
databases with the information
on their type, the total number of
cases (patients or biosamples)
for all diseases collected in the
database, date of last data
update, and the country (lower
right). b The “Search” tab is
particularly useful for searching
the numbers of cases with the
disease of interest in each found
database (marked in red)
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or by single diseases (e.g., Duchenne and Becker muscular
dystrophy).
For the scope of data sharing, the use of a more
detailed description is encouraged
The “Documents” section contains relevant documents,
such as study protocols, case report forms, standard
operating procedures, informed consent templates,
approval by the research ethics committee, data transfer
agreements, and publications. When available, registries
provide templates to request access (i.e., Material and Data
transfer Agreement – MTA, DTA) that can be used to
contact the database.
To help users navigate the Registry & Biobank Finder
and other systems, RD-Connect provides video tutorials on
its YouTube channel (https://www.youtube.com/channel/
UCwwcUPJZfyWGaW13Lvao7Ag). This includes a tutor-
ial for end users on how to browse the Registry & Biobank
Finder as well as a tutorial addressed to registry and bio-
bank managers, demonstrating how to add their database to
the Finder.
Population of the RD-Connect Registry & Biobank
Finder
A backend database was ﬁrst created with mapping of
existing RD registries and biobanks starting from
existing inventories (see Table 1). An invitation strategy
was planned in order to increase the probability of
acceptation and the success of the RD-Connect ID-Cards
(Fig. 4)
Inclusion of registries
Based on the mapped registries, RD-Connect curators
invited as early adopters the databases that were familiar
with the program, in the endeavor to get a “snowball effect”.
In particular, the invitation was directed to registries in
the RD-Connect Core Implementation Group (CIG) [35],
some of which also tested the system and provided feed-
back, registries collaborating with the US National Center
for Advancing Translational Sciences (NCATS) Global
Rare Disease Patient Registry Data Repository (NIH/
NCATS/GRDR) program [36], registries collaborating with
the RD-Connect project partner Invitae (formerly, Patient-
crossroads) [35], and registries participating to the RD-
Connect partner projects NeurOmics [17] and EURenOmics
[18].
The registries that accepted the invitation were evaluated
according to three main criteria:
1. Relevance: The registry should be relevant for the
study of RDs and include clinical data; registries
dealing with common diseases and registries that were
not focused on clinical outcomes (i.e., on the
experience of illness) were excluded.
2. Accessibility: Information about the registry should
Address of 
the registry 
or biobank.
Fig. 3 An ID-Card of an
individual database. The detailed
description of each registry or
biobank in the directory is
presented as an ID-Card with the
address and three tabs:
“Overview”, “Diseases” and
“Documents”. “Overview”
provides general information
about the database, such as the
contact data, source of funding,
target population and
membership in networks.
“Diseases” opens a Disease
Matrix, which lists all the
diseases for which the registry/
biobank has collected data, with
the numbers of cases (patients or
donors) and the mutations
covered. The “Documents” tab
provides access to various
documents, such as database’s
data transfer agreement,
templates for informed consent
and publications
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be easily available, ideally on a project website, or on
the website of an organization (university, hospital,
etc.) or patient association. Information could be also
displayed in clinicaltrial.gov, Orphanet, or in works
published by controlled and updated sources (peer
reviewed journals, periodic reports, etc.). The regis-
tries for which no information or poor or old
information was available were excluded.
3. Quality: High-quality data are considered to be one of
the most important elements in the establishment and
maintenance of a registry. Data quality control is
possible through a systematic examination of data
(internal or external audit process) against a number
of dimensions: completeness; validity; coherence and
comparability; accessibility; usefulness; timeliness
and prevention of duplicate records. Since it is
impossible for curators to evaluate directly the quality
of a registry, two elements were considered: avail-
ability of information on standards and procedures for
quality management and availability of peer reviewed
publications. The last point was considered as
particularly relevant as most databases that are
disseminating their results have undergone a quality
check through the peer review process and they may
be more keen to share other data in the future [36].
However, since registries are only asked to share
aggregated data in the Finder, quality evaluation was
rather permissive in this phase of the project, with the
plan to intensify quality checks for those registries
that will decide to share de-identiﬁed data in the
future.
Since the end of 2015, the Finder has been open to
receive online submissions through the “Propose” section, as
described above, and 8 registries have been added to the
directory after curators’ evaluation and approval, and self-
completed by the proponents.
As of November 2017, the RD-Connect Registry &
Biobank Finder included aggregated data of more than 222
RD registries from around the world with a strong
no
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Biobank Registry
Mapped
databases
Reject
Accept
Fill and 
submit
Meet minimum 
criteria
A panel 
reviews the 
informaon
Links to the online 
biobank assessment
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Evaluaon by curators
for Relevance, 
Accessibility and Quality
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Feedback
Feedback 
Email invitaon
login credenals
Database 
self proposal
ID-Card creaon
355
9
2
360
13
8
21
2
ID-Card
complete  
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Regular updates
22221
Fig. 4 Inclusion of biobanks and
registries in the Registry &
Biobank Finder. The process of
inclusion and evaluation of
biobanks and registries in the
Registry & Biobank Finder
(mapped and self-proposed)
Table 2 RD registries by country and dimension
RD registries by
country and
dimension
No (%)
Country
Australia 5 (2.3)
Austria 3 (1.4)
Belgium 2 (1)
Bulgaria 10 (4.5)
Canada 4 (1.8)
Czech
Republic
5 (2.3)
France 17 (7.7)
Germany 13 (5.9)
International 40 (18)
Ireland 3 (1.4)
Italy 28 (12.6)
Japan 2 (1)
Spain 10 (4.5)
United
Kingdom
12 (5.4)
United States 55 (24.8)
Others 13 (5.9)
Dimension (no. of cases included)
>5000 13 (5.9)
1000–5000 61 (27.5)
500–1000 41 (18.5)
100–500 82 (36.9)
<100 25 (11.3)
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participation of US registries (24.8%), followed by Inter-
national registries (18%), Italian (12.6%), French (7.7%),
German (5.9%), United Kingdom (5.4%), and Spanish
registries (4.5%) (Table 2).
Included registries are categorized into ﬁve main sizes or
dimensions, according to the number of cases included:
<100, 100–500, 500–1000, 1000–5000, and >5000. The
most frequent dimension in participating registries was the
one counting 100–500 registered cases (Table 2). The most
represented disease categories in RD registries are rare
neurological diseases (17.1%), rare neuromuscular diseases
(14%), rare hematological diseases (11.3%), rare pulmonary
diseases (9.5%), rare renal diseases (8.1%), and rare her-
editary metabolic disorders (7.2%) (Table 3).
Two registries have opted out indicating their wish not to
be involved.
Inclusion of biobanks
All RD biobanks can apply to participate in the RD-Connect
Platform and be included in the Registry & Biobank Finder.
The potential and beneﬁts of the RD-Connect Platform for
biobanks are explained in the promotional video (https://
youtu.be/tLbn0748shk). To ensure that RD researchers have
access to high-quality biological samples, participating RD
biobanks undergo an assessment to ensure a set of minimum
criteria is met (Fig. 4). The biobank assessment process was
adapted from the EuroBioBank, a recognized European
high-quality RD biobank network, from its membership
application model [28]. RD-Connect Registry & Biobank
Finder serves as the portal to manage this assessment pro-
cess. Self-proposed and invited RD biobanks receive indi-
vidual access to the online questionnaire, which includes
questions on the general information of the biobank
(Overview), disease focus, sample collections, use of bio-
banking SOPs, implementation of quality standards, col-
lection of informed consent, management, and availability
of their sample catalogue. Some answers from the ques-
tionnaire then form a base of the information on the bio-
banks provided in the Finder. A sample of the questionnaire
is available on the RD-Connect website (www.rd-connect.
eu) with a video tutorial explaining the application process
(https://youtu.be/x5b70fLY5L8). The RD biobanks are
required to accept the terms laid out by the RD-Connect
Code of Practice [37], a document that contains deﬁnitions
and governance responsibilities of participants on data
usage across the RD-Connect Platform. A declaration by the
biobanks to share their sample data sets is considered
compulsory as a part of participation to RD-Connect.
Once the biobank submits the completed ques-
tionnaire, the curator forwards the application to the RD-
Connect Biobank Assessment Panel. The panel is com-
posed of experts in the ﬁeld of RD biobanking, biobank
IT infrastructure, and a patient representative, who pro-
vides independent review on their own personal capa-
cities. The panel reviews the application and the outcome
of whether the minimum criteria (RD focus, sample
quality assurance plans, use of informed consent, evi-
dence of biobanking activity, and the curriculum of the
biobank director) for participation are met is fed back to
the biobank within 4 weeks. Once the acceptance notiﬁ-
cation has been sent, the curator publishes the biobank’s
ID-Card, rendering it visible to users. Successful bio-
banks subsequently receive information to assist them in
uploading data related to their sample collections to the
RD-Connect Sample Catalogue.
The ﬁrst biobank ID-Card was published in February
2015. Before moving on to invite RD biobanks mapped by
RD-Connect, two associated partner biobanks of the project
were asked to test the portal and provide feedback on
usability and clarity of the questions for biobank assess-
ment. Amendments were made to the portal, and similarly
to the RD registries, priorities were given to include project
collaborators and associate partner biobanks. The ﬁrst
invitations were extended to EuroBioBank members [28].
Since the opening of the portal, it has also received online
self-proposals from seven biobanks via the “Propose” sec-
tion. These expressions of interest from RD biobanks to
Table 3 Distribution of RD registries according to disease category
RD registries by disease categorya No (%)
Rare bone diseases 5 (2.3)
Rare cancers and tumors 11 (5)
Rare connective tissue and musculoskeletal diseases 2 (0.9)
Rare craniofacial anomalies and ENT (ear, nose and
throat) disorders
1 (0.5)
Rare endocrine diseases 4 (1.8)
Rare eye diseases 6 (2.7)
Rare gastrointestinal diseases 3 (1.4)
Rare hematological diseases 25 (11.3)
Rare hepatic diseases 5 (2.3)
Rare hereditary metabolic disorders 16 (7.2)
Rare immunological and auto-inﬂammatory diseases 10 (4.5)
Rare malformations and developmental anomalies and
rare intellectual disabilities
17 (7.7)
Rare multi-systemic vascular diseases 3 (1.4)
Rare neurological diseases 38 (17.1)
Rare neuromuscular diseases 31 (14)
Rare pulmonary diseases 21 (9.5)
Rare renal diseases 18 (8.1)
Rare skin disorders 1 (0.5)
Rare urogenital diseases 1 (0.5)
Others 4 (1.8)
aAddendum to EUCERD Recommendations of January 2013
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participate were prioritized for processing and assessment.
By 21 November 2017, biobank ID-Cards have been pub-
lished, including two biobanks who self-proposed and were
positively evaluated.
Discussion
RD-Connect aims to promote the culture of data sharing
among RD researchers. RD-Connect Registry & Biobank
Finder enables more intensive sharing of patient disease
information and biosamples. Researchers can ﬁnd registries
and biobanks storing disease data or biosamples for their
disease of interest. Database managers working on the same
or related RDs can increase mutual visibility, paving the
way to new scientiﬁc collaborations. It also allows
researchers to ﬁnd registries and biobanks storing data or
biosamples for their disease of interest.
In its ﬁrst phase of activity, the Registry & Biobank
Finder has made an increasing amount of aggregated data
and metadata from participating databases available, thus
contributing to making RD registry and biobank data more
ﬁndable, accessible, interoperable and reusable (FAIR) [38].
By displaying the number of cases included in participating
databases, as well as the connections between participating
biobanks and registries, the Registry & Biobank Finder is
making RD data more “ﬁndable”. It is making biobank data
more “accessible” by providing a link to the RD-Connect
Sample Catalogue. Furthermore, propagating access infor-
mation as it is provided by the registered sources ﬁts a
federated model, letting registries maintain the prerogative
to decide on providing access (or not) upon request. The
ﬁnder can contribute to “interoperability” by standardizing
the minimum information that it collects, but to fully exploit
its capabilities also the sources must be “interoperable”.
Therefore, RD-Connect and ELIXIR support contributors
with tools and training activities such as “Bring Your Own
Data” workshops (BYOD) and the International Summer
School on RD registries [39]. The RD-Connect platform
and ELIXIR website provide more information. Finally, we
are working on a FAIR Data Point API for the Registry &
Biobank Finder to enable retrieval of data in linkable for-
mat, particularly via the resource description framework and
richly annotated with ontologies. This addresses the
machine-readability criterion of FAIR data and renders the
data from the ﬁnder more “reusable” for future analyses
across multiple sources.
However, some barriers to participation have become
apparent especially for registries, as not all invited regis-
tries are replying to the invitation and among participants
not all are completing their ID-Cards and in particular the
DM. Indeed, of the 222 registries with a complete DM,
less than half were provided upon personal communication
(44%), while in most cases data were retrieved by ﬁnder
curators in the registry’s website (21%) and in published
papers (33%).
We speculate that the most probable reason for this
barrier is the lack of available time researchers have to
complete and update the proﬁles.
Other barriers to participation reported by PIs and registry
curators include the need to ask permission to the registry
steering committee or governing board before revealing
aggregated data and metadata to the ﬁnder and no foreseen
advantage in making aggregated data publicly available.
While the general advantages of data sharing for the
scientiﬁc community are easily understood, the advantages
of data sharing for researchers may not be immediately
proﬁtable even though funding agencies [40–43], journals
[44], and scientiﬁc societies [45] are promoting data sharing
among scientists at all levels.
Several tentative strategies were put in place to increase
participation:
(1) make more targeted invitations, i.e., disease or event
related; (2) send periodic newsletters; (3) organize training
courses for participants; (4) reduce registry owners’ efforts
by pre-ﬁlling the DMs of registries; however, this implies
an increased effort for curators.
Stronger incentives to participation would consist in
creating opportunities for more citations in high-impact
journals but also outside conventional metrics [46]. For
example, in the biobank setting, the sharing of bioresources
is incentivized by the BRIF initiative (Bioresource Research
Impact Factor project), which consists in keeping a link
between the initiators/implementers of a bioresource and the
impact of the biological resource in scientiﬁc/academic
publications [47].
The same tools and principles could be easily applied to
registry data, to maximize their accessibility and reuse while
recognizing efforts involved in their maintenance.
Another possibility to promote participation, already dis-
cussed in appropriate forums, would be to provide economic
incentives to databases, in the form of fees for single data
access requests or more extensive subscriptions with third
parties, including access by third parties to part of the data or
to the entire database for a determined period of time, and
related to a speciﬁc research project. Pay-for-access services
would be offered to different stakeholders, such as
“data hunting” companies and Centres for Research Organi-
zations, pharmaceutical companies, foundations, researchers
working in academia, and in other public or non-proﬁt
organizations.
The Registry & Biobank Finder may support registries in
agreeing a “rate table” (price list) according to the rarity of
the disease and according to the kind of data released: i.e.,
aggregate data or statistics; unit record data; linked data;
access to a patient recruitment service for clinical trials, etc.
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As foreseen in important health data repositories like
some National Cancer Services [48, 49], additional costs
may be foreseen for the more complex and time-consuming
requests (e.g., for rich annotation with ontologies) to cover
platform or registry’s costs of retrieving and processing
data. Otherwise, to support the most accessible but least
accessed databases, the Registry & Biobank Finder might
consider linking ﬁnancial support for registries according to
predeﬁned accessibility proﬁles starting from databases
sharing very general aggregated data to those sharing more
detailed aggregated data (i.e., by patient’s age, sex, age at
onset, etc.), to those also sharing patient de-identiﬁed data.
However, this approach would require that the ﬁnder
centralizes and mediates access requests and permissions
for registries, which is beyond the current scope of the
project.
Participation response from RD biobanks was more
positive in comparison to registries. This may have resulted
from the limited number and heterogeneity of participating
biobanks, as well as from the intrinsic nature of biobanks to
distribute biological samples for research, where a culture of
sharing and the need to be visible already exist [49]. Bio-
banks are also becoming aware of the paradigm shift in the
genomic era, where research has become more data intensive
and huge amounts of NGS and -omics data derived from
biological samples are generated as a part of personalized
medicine research [50]. Importantly, biobanks are poised to
respond to new opportunities and demands by developing
new business plans, partnerships, and cost recovery models,
to ensure that sustainability and relevance of the
biobank operation is maintained [51–53]. The RD-Connect
Platform provides an opportunity for RD biobanks to enrich
their data sets by linking RD biological samples to pheno-
typic and -omics data. As RD biobanks tend to be small
units with limited resources, participating biobanks can easily
recognize the beneﬁt from being in a supported
community created by the RD-Connect project, for a shared
effort in data harmonization and learning from experiences
[28].
RD-Connect and the Registry & Biobank Finder represent
a driving case for developing life science data infrastructure
[16]. The low frequency of rare disease cases and the scat-
tering of rare disease data resources across institutes and
countries, combined with the consequential need to combine
data within legal and ethical constraints, provide an excellent
target for developing a federated data infrastructure.
As the number of data sharing initiatives increases,
researchers, pharmaceutical companies, and regulators also
see value in supporting these initiatives and we may agree
that “data sharing, in one form or another, is becoming
inevitable” [54].
There are several kinds of users and potential uses for the
RD-Connect Registry & Biobank Finder, including
academic researchers and researchers collaborating with the
industry, dealing with the questions of basic, translational,
and/or clinical research.
Every effort must be done in order to keep the dialog
open to internal and external users’ requests and solicita-
tions in order to reply to their research questions in a
satisfactory way.
The Registry & Biobank Finder provides an
essential building block in the global infrastructure for the
RD domain. It makes biobanks and registries across the
globe ﬁndable in a controlled manner, and gives
stakeholders, including clinicians, researchers, and funders,
access to key information about these resources. This can
foster collaboration and allow valorization of the
registered sources. RD-Connect and the Registry & Bio-
bank Finder must also keep patients and families involved
in their development since they are the main actors of RD
research.
The increased sharing and moving of patients’ data and
samples across national borders through dedicated plat-
forms like RD-Connect is to be acknowledged by patients
and their families, who must be informed on all foreseen
beneﬁts and risks of international collaboration among RD
researchers. This can be done via the informed consent
process to participate in registries and biobanks, including a
description and an explanation of data sharing platforms
like RD-Connect, but also through the active involvement
of patient representatives and patient organizations in the
governance and advisory activities [55].
The possibility to share more aggregated data and match
patient data with data on the same patient coming from
other databases via the use of unique identiﬁers [56], which
is foreseen in the development of the RD-Connect platform,
requires dynamic solutions for the informed consent and
return of secondary ﬁndings to patients [57]. We are
therefore investigating how machine-readable consent that
is directly attached to data elements can be used to check
consent efﬁciently [58].
The design and development of the RD-Connect Reg-
istry & Biobank Finder is related to the activity of the RD-
Connect project, which warrant its sustainability until the
end of 2018. Solutions are under study for the long-term
maintenance, growth, and stability of the Registry & Bio-
bank Finder, including the involvement and support of
Orphanet [33], of the European platform for rare diseases
registries that is under study at the Joint Research Centre
[59], the involvement of ERNs, which are required to pro-
mote collaborative research within the Network and rein-
force research and epidemiological surveillance, through
setting up of shared registries [26, 27] and the inclusion of
its activities in the framework of ELIXIR [16] and an
existing European Research Infrastructures Consortium
(ERIC) such as BBMRI-ERIC [15].
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